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Purpose: The human cornea is a primary target for herpes simplex virus-1 (HSV-1) infection. The goals of the study were
to determine the cellular modalities of HSV-1 entry into human corneal epithelial (HCE) cells. Specific features of the
study included identifying major entry receptors, assessing pH dependency, and determining trends of re-infection.
Methods: A recombinant HSV-1 virus expressing beta-galactosidase was used to ascertain HSV-1 entry into HCE cells.
Viral replication within cells was confirmed using a time point plaque assay. Lysosomotropic agents were used to test for
pH dependency of entry. Flow cytometry and immunocytochemistry were used to determine expression of three cellular
receptors - nectin-1, herpesvirus entry mediator (HVEM), and paired immunoglobulin-like 2 receptor alpha (PILR-a). The
necessity of these receptors for viral entry was tested using antibody-blocking. Finally, trends of re-infection were
investigated using viral entry assay and flow cytometry post-primary infection.
Results: Cultured HCE cells showed high susceptibility to HSV-1 entry and replication. Entry was demonstrated to be
pH dependent as blocking vesicular acidification decreased entry. Entry receptors expressed on the cell membrane include
nectin-1, HVEM, and PILR-α. Receptor-specific antibodies blocked entry receptors, reduced viral entry and indicated
nectin-1 as the primary receptor used for entry. Cells re-infected with HSV-1 showed a decrease in entry, which was
correlated to decreased levels of nectin-1 as demonstrated by flow cytometry.
Conclusions: HSV-1 is capable of developing an infection in HCE cells using a pH dependent entry process that involves
primarily nectin-1 but also the HVEM and PILR-α receptors. Re-infected cells show decreased levels of entry, correlated
with a decreased level of nectin-1 receptor expression.
Herpes  simplex  virus  (HSV)  is  a  member  of  the
alphaherpesvirus  subfamily  and  has  the  ability  to  cause
several ocular infections [1-3]. Primary infection of the virus
spreads  from  cutaneous  lesions  or  infections  of  mucosal
surfaces to neuronal cell bodies, establishing a latent, lifelong
infection. Specifically, herpes simplex virus 1 (HSV-1) is the
cause of over 95% of cases of ocular herpes [2]. Infection
generally occurs unilaterally and it remains the leading cause
of infectious blindness in developed nations, partly due to its
ability to latently infect hosts for long periods of time [1,2].
More than 20,000 new cases of ocular HSV-1 infection and
an additional 28,000 reactivations occur in the United States
annually  [2].  HSV-1  infection  causes  a  variety  of  ocular
diseases  including  blepharitis,  conjunctivitis,  epithelial
keratitis, stromal keratitis, endotheliitis and iridocyclitis –
some of which pose a severe visual threat to infected hosts
[2,3].
The corneal epithelium represents one of the major host
sites of infection for HSV-1 and may precede infection of
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other locations within the eye [2]. The epithelium is composed
of several layers of cells that protect the cornea's deeper layers,
notably the stroma, and thus lies in the dominant pathway of
infection by exogenous virus. The cornea is also the most
highly  innervated  tissue  in  the  body,  facilitating  the
development of latency in trigeminal ganglia via retrograde
transport of HSV. Some authors suggest that the cornea itself
may be a site of latency, predisposing patients to increased
morbidity resulting from localized viral reactivation [4-6]. Its
continuity with the conjunctival epithelium further aides in
the spread of virus in ocular infection [4]. While having such
a critical role in ocular HSV, little is known of the mechanism
of HSV-1 entry into human corneal epithelial cells.
This issue is particularly significant due to the potential
for corneal infection to cause visual morbidity [7]. While
epithelial  keratitis  can  cause  acute  symptoms  it  also
predisposes to stromal keratitis, which in turn can lead to
scarring and opacification despite treatment [7,8]. While a
minority of patients with initial ocular herpes infection present
with stromal keratitis, it is much more frequent in the recurrent
form of the disease and accounts for a significant portion of
patients who develop blindness [1,2]. Thus, prevention of
epithelial infection and its subsequent sequelae could improve
the visual prognosis of patients.
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2476Penetrating keratoplasty remains the most successful and
most  commonly  practiced  form  of  human  tissue
transplantation [9]. HSV keratitis is an important indication
for corneal transplantation and is also a cause of graft failure
[10]. There have been rare reports of donor-host transmission
of HSV, which may be related to corneal latency [11]. It is
suggested that the transplant procedure itself may be able to
trigger latent virus to reactivate [12]. Potential complications
following the procedure include recurrent herpetic keratitis
and secondary non-viral infection [9,13,14]. Although the
success  of  penetrating  keratoplasty  in  HSV  keratitis  has
improved,  understanding  the  mechanism  of  infection  is
important as future treatment options are investigated.
Significant knowledge of the molecular mechanisms of
HSV-1 infection in general has been obtained in previous
studies. Infection of HSV-1 into cells involves multiple cell
receptors  and  helper  proteins  found  on  the  virion;  these
receptors and proteins aid in binding, fusion and entry into the
target cell. At least five envelope glycoproteins are involved
in entry: gB, gC, gD, gH and gL [15]. Viral glycoproteins gB
and gC bind to the ligand receptor heparan sulfate which
allows  the  virus  to  attach  to  the  cell  [16].  Next,  a
conformational  change  in  the  viral  glycoprotein  structure
allows glycoprotein D (gD) to attach to its receptor (the gD
receptor) located on the target cell [15]. Fusion of the viral
envelope  with  the  target  membrane  then  occurs  with  the
combined effects of gD, the gD receptor, gB, gH, gL, and
possibly the gH coreceptor [15,17]. Once this series of events
is initiated, fusion of the virion with the plasma membrane can
occur via a pH independent process. In some cell types, a pH
dependent pathway has been described with an endocytic
mode of entry [18].
The importance of the gD receptors in entry is therefore
a result of the role of gD as a catalyst. Among these, nectin-1
(HveC) and nectin-2 (HveB) belong to a distinct class of
receptors  in  the  immunoglobulin  superfamily.  Nectin-2,
however, only aids in the entry of generated mutant strains of
HSV-1 and not wild-type strains of the virus [15]. Herpesvirus
entry mediator (HVEM) also associates with gD and belongs
to the tumor necrosis factor receptor family [19]. 3-O sulfated
heparan sulfate is a rare modified form of heparan sulfate that
acts as a gD receptor for HSV entry into certain cell types and
has antithrombotic properties [20]. paired immunoglobulin-
like 2 receptor alpha (PILR-a) has been suggested to act as an
entry receptor, but recent data suggests it may act more as a
co-receptor [21].
While infection of the corneal epithelium is clinically
important,  little  is  known  about  how  HSV-1  enters  into
corneal  epithelial  cells  despite  improved  knowledge  of
neuronal reactivation [22]. It is also unknown to what extent
virus-cell interactions in the corneal epithelium play a role in
determining  the  course  of  disease.  This  study  aims  to
determine the receptors that facilitate HSV-1 entry into human
corneal epithelial cells and determine whether entry is pH
dependent. After identifying the major molecular and cellular
mechanisms of infection, this study aims to investigate re-
infection of corneal epithelial cells and determine whether
exposure to virus affects the ability of secondary infection to
occur at early time points. The study then aims to determine
if receptor expression is altered during re-infection.
METHODS
Cells, viruses, and antibodies: The human corneal epithelial
(HCE) cell line (RCB1834 HCE-T) was obtained from Dr.
Kozaburo Hayashi (National Eye Institute, Bethesda, MD)
[23].  The  cells  were  grown  in  Minimal  Essential  Media
(MEM;  Gibco-Invitrogen  Corp.,  Rockville,  MD)  and
supplemented with penicillin, streptomycin, and 10% fetal
bovine serum (FBS).
The African green monkey kidney (Vero) cell line as well
as the wild-type Chinese hamster ovary (CHO-K1) cell lines
were obtained (Patricia G. Spear, Northwestern University,
Chicago, IL) and cultured as previously decribed [19]. The
viruses used in the study – HSV-1(KOS), HSV-1(KOS)804,
HSV-1(KOS)gL86,  and  HSV-1(KOS)RFP  –  were  also
provided by Patricia G. Spear [19]. All virus stocks were kept
at a low multiplicity of infection (MOI), propagated in Vero
cell lines, and stored at −80 °C. Titers for all three of the
viruses were determined using Vero cells as well.
Anti-nectin-1 antibodies used were monoclonal mouse
anti-nectin-1 (37–5900; Zymed Laboratories, San Francisco,
CA).  The  monoclonal  mouse  anti-HVEM  antibody  was
obtained from Santa Cruz Biotechnology (sc-74089; Santa
Cruz, CA) and the monoclonal rat anti-PILR- α was obtained
from  Dendritics  (ddx0230;  Lyon,  France).  The  secondary
antibodies  FITC-conjugated  anti-mouse  IgG  and  FITC-
conjugated anti-rat IgG were obtained from Sigma-Aldrich
(St. Louis, MO).
Viral entry assays: Viral entry assays were performed using
both HCE cells and naturally-resistant CHO-K1 cells, the
latter of which do not possess the known viral entry receptors.
Cells  were  plated  on  a  96-well  tissue  culture  dish  at  full
confluency (approximately 2×104 cells per well). Cells were
then  infected  with  serial  dilutions  of  β-galactosidase
expressing HSV-1(KOS)gL86 virus at a maximum MOI of
0.01 in a solution of 3% BSA (BSA) in phosphate buffered
saline (PBS). After 6 h of infection, cells were washed with
1×  PBS  and  then  incubated  with  o-nitrophenyl-  β-D-
galactopyranoside (ImmunoPure ONPG; Pierce, Rockford,
IL),  thus  allowing  quantification  of  β-galactosidase
expressing HSV-1(KOS)gl86 viral entry into each of the cell
types. Measurements of activity were then obtained at an
optical density of 410nm by a spectrophotometer (Molecular
Devices, Sunnyvale, CA).
HSV-1  entry  into  HCE  and  CHO-K1  cells  was  then
confirmed qualitatively by 5-bromo-4-chloro-3-indolyl-β-D-
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2477galactopyranoside (X-gal) assays. Monolayers of cells were
plated in a 6-well tissue culture dish (approximately 1.5×106
cells per well). Cells were again infected for 6 h using the
HSV-1(KOS)gL86 virus. After the incubation period, cells
were washed, fixed, permeabilized, and incubated with the X-
gal substrate. The X-gal substrate forms a blue color with cells
that  contain  β-galactosidase.  Microscopy  images  were
collected using a 20× objective from the inverted microscope
(Aciovert 100M; Zeiss, Jena, Germany) with the software
Slidebook, version 3.0.
Time point plaque assay: Viral entry and replication were
again confirmed using a time point plaque assay. Monolayers
of HCE, CHO-K1, and Vero cells were plated on a 6-well
tissue culture dish (approximately 1.5×106 cells per well).
Cells were infected at 0.01 MOI with HSV-1(KOS)804 virus
or  mock  infected  with  1×  PBS  for  2  h.  After  primary
incubation, the viral or mock solution were replaced with the
proper media for each cell type – MEM with 10% fetal bovine
serum (FBS) and penicillin/streptomycin additives for HCE
cells,  Ham's  F-12  medium  with  10%  FBS  and  penicillin/
streptomycin additives for CHO-K1 cells, and DMEM with
10% FBS and penicillin/streptomycin additives for Vero cells.
Cells were then incubated at 37 °C for a series of time points.
At the time points of 0, 12, 18, 24, and 36 h, incubated cells
were fixed using 100% methanol and subsequently stained
with a solution of 1% crystal violet in 50% ethanol at room
temperature.  Cells  were  then  washed  three  times  with
nanopure water and the number and size of plaques were
assessed as a measure of viral replication. Plaque size was
measured and plotted as an average of 100 plaques formed at
each time interval. Plaques were not significantly formed by
the naturally-resistant CHO-K1 cells and thus plaque sizes
were not measured or plotted. Images of the plaques were
taken using the 40× objective from the inverted microscope
(Aciovert 100M; Zeiss) using the software Slidebook version
3.0.
pH dependence of entry: HCE cells were plated on a 96-well
tissue culture dish (approximately 2×104 cells per well). Cells
were then treated with serial dilutions of BFLA-1 (1 μM) or
chloroquine  (1  mM)  and  incubated  for  1  hat  37  °C.
Concentrations of BFLA-1 and chloroquine followed those of
previous studies [24,25]. Cells were then treated with equal
concentrations of HSV-1(KOS)gL86 virus. The viral entry
assay was then performed and β-galactosidase activity was
determined using the same protocol as described above.
Isolation of RNA: RNA was isolated from the Human Corneal
Epithelial  cells  and  CHO-K1  cells  with  TRIzol®  reagent
(Invitrogen, Carlsbad, CA). Total RNA samples were purified
by RNeasy Mini kit (Qiagen, Valencia, CA) according to the
manufacturer’s manual and checked the quantity of RNAs
using NanoDrop (Thermo Scientific, Wilmington, DE). The
quality  of  RNA  was  evaluated  by  NanoDrop  (Thermo
Scientific) and warranted that the ratio (28S/18S) of high RNA
quality  were  >1.5.  Densitometry  analysis  was  performed
using the NIH ImageJ software (version 1.43) and data for
relative intensity was plotted as a histogram.
Gene expression analysis and verification by qRT–PCR: To
examine the gene expression by quantitative RT–PCR, 10 µg
of  the  RNA  samples  from  HCE  and  CHO-Ki  cells  were
converted  to  first  strand  cDNAs  using  the  High-Capacity
cDNA  Reverse  Transcription  Kits  (Applied  Biosystems,
Foster City, CA) following the manufacturer’s protocol. The
cDNA  was  added  into  the  Platinum  SYBR  Green  qPCR
SuperMix-UDG Master Mixes (Invitrogen, Carlsbad, CA)
containing  SYBR  Green  I  fluorescent  dye  and  Taq  DNA
polymerase. The mixtures were aliquoted into 96-well plate
containing gene specific primer sets. The sequence of the
target gene primers included HVEM primers: 5′-TCT CTG
CTG CCA GAC A-3′ and 5′-GCC ACA GCA GAA CAG
A-3′, Nectin-1 primers: 5′-TCC TTC ACC GAT GGC ACT
ATC C-3′ and 5′-TCA ACA CCA GCA GGA TGC TC-3′,
PILR-α primers: 5′-AAG GTC AGC AGC GGA CTA AA-3′
and 5′-CAG TCT TGA GAG GGC TGT CC-3′, beta-actin
(ACTB)  primers:  5′-GTG  ATG  GTG  GGA  ATG  GGT
CAG-3′ and 5′-TTT GAT GTC ACG CAC GAT TTC C-3′.
The qRT–PCR reactions were performed using ABI Prism
7500  system  (Applied  Biosystems)  with  the  following
parameters; repeat 1 (1 cycle), 2 min at 50 °C; 2 min at 95 °C
and repeat 2 (40 cycles), 15 s at 95 °C and followed by 30 s
at 60 °C, and the data were collected at each 60 °C. PCR
products were ran on a 1% agarose gel, stained with ethidium
bromide and illuminated with UV light. Expected PCR gene
product sizes were 1,270 bp for HVEM, 738 bp for nectin-1
and 250 bp for PILR-α.
Immunocytochemistry: To visualize various receptors on the
cell surface, monolayers of HCE cells were plated on chamber
slides (Lab-Tek; Nunc, Rochester, NY) at 100% confluency.
After a 1× PBS wash, cells were incubated with anti-nectin-1
(1:50 dilution), anti-HVEM (1:50 dilution), or anti-PILR-α
(1:25 dilution) primary antibody for 90 min at 4 °C. After the
primary incubation period, cells were washed three times with
a cold solution of PBS containing 3% BSA for 10 min. Next,
cells were incubated with secondary antibody. The secondary
antibody used for the anti-nectin-1 and anti-HVEM primary
antibody was FITC-conjugated anti-mouse IgG (Sigma) while
the  secondary  used  for  anti-PILR-α  antibody  was  FITC-
conjugated  anti-rat  IgG  (Sigma);  all  secondary  antibodies
were administered at a concentration of 1:1,000 and had an
incubation period of 45 min at 4 °C. Cells were then washed
three times with a cold solution of PBS containing 3% BSA
for 10 min. Final products were imaged using laser-scanning
spectrum confocal microscopy (TCS SP2; Leica, Wetzlar,
Germany). HCE cells treated with only secondary antibody as
well as primary antibodies replaced with isotypes served as
negative controls. A monoclonal anti c-Myc IgG in generated
in mouse and a rat anti c-Myc IgG (Abcam) provided the
isotype controls.
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2478Flow cytometry: Flow cytometry was used to confirm the
presence of viral entry receptors nectin-1, HVEM, and PILR-
α on the cell surface visualized by immunocytochemistry.
Monolayers  of  HCE  cells  plated  on  6-well  tissue  culture
dishes  were  transferred  to  1.5  ml  Eppendorf  tubes  using
Hank's  based  enzyme-free  cell  dissociation  buffer
(Invitrogen) and were then washed three times for 10 min with
a cold solution of 1× PBS with 10% glucose and 10% calf
serum. Cells were then incubated at 4 °C for 90 min with either
anti-nectin-1 (1:100 dilution), anti-HVEM (1:100 dilution), or
anti-PILR-α (1:100 dilution) primary antibody. Cells were
again washed three times for 10 min with a cold solution of
1× PBS with 10% glucose and 10% calf serum and then
incubated for 45 min at 4 °C with the appropriate FITC-
conjugated  secondary  antibody  as  noted  above  at  a
concentration  of  1:1,000.  After  incubation  of  secondary
antibody, the cells had a final wash for 10 min with a cold
solution of 1× PBS with 10% glucose and 10% calf serum.
Flourescence-activated cell sorter (FACS) analysis was then
performed.
Antibody blocking of receptors: HCE cells plated on a 96-well
tissue culture dish (approximately 2×104 cells per well) were
treated with serial dilutions of the appropriate antibody (anti-
nectin-1,  anti-HVEM,  or  anti-PILR-α)  to  block  their
corresponding receptor. The dilutions of the antibodies used
ranged from 1:25 to 1:1600. Following incubation at room
temperature for 2 h, viral entry assays were performed using
HSV-1(KOS)gL86 virus as per the protocol stated above.
Cells  not  blocked  with  primary  antibody  were  used  as
controls.
Re-infection: HCE cells plated on a 96-well tissue culture dish
(approximately  2×104  cells  per  well)  were  treated  with  a
primary viral dose of HSV-1(KOS) at a concentration of 0.01
PFUs/cell. After 48 h of incubation at 37 °C, cells were treated
with  a  serial  dilution  of  a  secondary  viral  dose  of
HSV-1(KOS)gL86.  Viral  entry  assays  were  subsequently
performed as per the protocol above. Cells treated with only
the secondary dose of virus served as controls. To determine
the proportion of cells infected during the primary infection,
cell staining was performed. HCE cells plated in a 6-well
culture dish at full confluency were treated with a viral dose
of HSV-1(KOS) at a concentration of 0.01 PFUs/cell. After
48 h of incubation at 37 °C, cells were rinsed with 1× PBS
wash.  Primary  HSV-1  polyclonal  antibody  (Dako,
Carpinteria, CA) was added at a 1:50 dilution and incubated
for 1 h at room temperature. After a 1× PBS wash, endogenous
Figure 1. SV-1 can enter into culture HCE cells. A: Dose response curve of HSV-1 entry into HCE cells. Cultured HCE cells along with
naturally HSV-1 resistant CHO-K1 cells were plated in 96-well culture dishes and inoculated with twofold serial dilutions of β-galactosidase-
expressing recombinant HSV-1(KOS)gL86 virus at the plaque forming units (PFU) indicated. After 6 h, the cells were washed, permeablized
and incubated with ONPG substrate. Viral entry was measured using a spectrophotometer which measured beta-galactosidase activity at an
optical density of 410 nm. Values in the figure were plotted as the mean of three determinations (±SD). B: Confirmation of HSV-1 entry into
HCE  cells  by  X-gal  staining.  HCE  cells  grown  (4×106  cells)  in  six  well  dishes  were  inoculated  with  β-galactosidase-expressing
HSV-1(KOS)gL86 virus at 20 PFU/cell. CHO-K1 cells were also infected in parallel as a negative control. After 6 h of infection at 37 °C,
cells were washed, fixed, and permeabilized. X-gal was then added which yields an insoluble blue product upon hydrolysis by β-galactosidase.
Blue cells, which represent cells with viral entry, were seen in HCE cells, but not the naturally resistant CHO-K1 cells. Microscopy was
performed using a 20X objective of the Zeiss Axiovert 100 microscope. The slide book version 3.0 was used for the images.
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2479peroxidase  activity  was  blocked  by  adding  3%  hydrogen
peroxide for 10 min at room temperature. After another 1×
PBS  wash,  secondary  anti-HSV-1  antibody  conjugated  to
horseradish  peroxidase  (1:200  dilution)  was  added  and
incubated for 30 min at room temperature. After a final wash,
DAB was added. Cells infected with virus were stained brown.
The proportion of infected cells in 100 high power fields were
determined and averaged.
Flow cytometry post-primary infection: HCE cells plated on
a 6-well tissue culture dish were treated with a viral dose of
HSV-1(KOS)RFP at a concentration of 0.01 PFUs/cell. After
48 h of incubation at 37 °C, the monolayers of cells were
transferred to 1.5 ml Eppendorf tubes. Before FACS analysis
was performed, cells were treated with propidium iodide to
distinguish live from dead cells. Flow cytometry was then
selectively performed to test levels of nectin-1 on living cells
tagged  with  red  flourescent  protein  as  per  the  method
described above. The concentration of anti-nectin-1 primary
antibody was 1:100 and the concentration of anti-mouse IgG
secondary antibody was 1:1,000. HCE cells untreated with a
viral dose were used as a control.
Statistical analysis: All of the experiments were conducted a
minimum of 3 times with results at a steady level. Quantitative
data was expressed as a mean±standard deviation.
RESULTS
HSV-1 entry and replication in HCE cells: As shown in Figure
1A, viral entry into HCE cells compared to that of CHO-K1
cells followed a dose-dependent pattern, with maximum entry
occurring  before  maximum  viral  concentration.  Upon
establishing initial data on viral entry using these results, viral
entry  was  verified  using  the  insoluble  substrate  X-gal.  In
Figure 1B, β-galactosidase activity was not observed in the
naturally resistant CHO-K1 cells, whereas β-galactosidase
activity was observed in HCE cells (Figure 1C).
After establishing HSV-1 viral entry into HCE cells, we
examined the ability of HSV-1 to successfully replicate within
the cells using a time point plaque assay. As seen in Figure
Figure 2. HSV-1 can successfully grow
and replicate in HCE cells. Confluent
monolayers  of  HCE,  Vero,  and
naturally-resistant CHO-K1 cells were
infected  with  HSV-1(KOS)804  at  an
MOI  of  0.01  for  90  min  at  37  °C.
Innoculums were harvested, fixed, and
stained at 0, 12, 18, 24, and 36 h. Data
represents  the  mean  of  three  samples
(±SD). A typical plaque formed by Vero
and HCE cells stained with crystal violet
at  18  h  of  infection  with
HSV-1(KOS)804 virus is shown in (B)
and (C) accordingly. Plaques were not
formed in the HSV-1 resistant CHO-K1
and the lack of plaques are shown in D.
Increasing  plaque  size  over  time
demonstrating  progressive  infection
was confirmed in E.
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24802A, the number of plaques followed a time-dependent pattern
for  HCE  cells  and  Vero  cells  (positive  control).  Image
confirmation of plaques after 18 h post-infection in Vero and
HCE cells are demonstrated in Figure 2B,C, respectively.
Figure  2D  confirms  that  plaques  were  not  formed  in  the
naturally  resistant  CHO-K1  cells  at  18  h  post-infection.
Plaque size was also measured at the time intervals of 12, 18,
and 24 h and plotted in Figure 2E. An increase in average
plaque size at successive time points was observed indicating
the ability of virus to spread to adjacent uninfected cells,
which is also observed during a primary or recurrent infection
in the cornea [26].
pH  dependency  of  viral  entry:  HSV-1  entry  can  be  pH
dependent  or  independent  depending  on  cell-type  [18].
Bafilomycin and chloroquine are both lysosomotropic agents
that increase pH and therefore influence cellular uptake in pH
dependent  mechanisms  (e.g.,  endocytosis).  As  shown  in
Figure 3, both bafilomycin and chloroquine strongly inhibited
HSV-1  entry  in  a  dose-dependent  manner;  when
concentrations  of  these  lysosomotropic  agents  were
increased,  measurements  of  viral  entry  decreased.  This
suggests  that  HSV-1  entry  into  HCE  cells  requires
acidification.
Identification and expression of entry receptors: To explore
the molecular basis for entry, we decided to examine entry
receptor expression by quantitative RT–PCR. It was evident
that genes for HVEM, Nectin-1 and PILRalpha were clearly
expressed by HCE cells (Figure 4A). Densitometry confirmed
gene expression of all three receptors as well (Figure 4B). The
control,  CHO-K1  cells,  showed  possible  expression  of
PILRalpha but not HVEM or nectin-1. As expected, both cell-
types expressed β-actin. The results from CHO-K1 cells are
consistent with previous findings [21]. Next, we decided to
verify  the  gene  expression  results  by  protein  expression
analysis using immunofluorescence and flow-cytometry. As
shown in Figure 5A,C,E, respectively, HCE cells express
nectin-1, HVEM, and PILR-α along the cell membrane. Cells
treated  with  only  FITC-conjugated  secondary  antibody  as
negative controls (Figure 5B,D,F, respectively) did not show
fluorescence and likewise, isotype control experiments also
did not result in any signals (data not shown). The expression
of all three receptors was also confirmed by flow cytometry
and is demonstrated in Figure 6. While the intensity of positive
cells  in  the  x-axis  is  somewhat  low,  these  results  were
reproducible  and  confirm  our  findings  from
immunofluorescence (Figure 5). The expression of nectin-1
was most abundant, followed by HVEM and PILR-α.
Antibody  blocking  and  down-regulation  of  receptors:
Reduction of viral entry with blocking by receptor-specific
antibodies  would  indicate  the  role  of  those  receptors  in
pathogenesis. The results shown in Figure 7 indicate that there
is remarkably diminished entry when any of the receptors
(nectin-1,  HVEM,  and  PILR-α)  are  blocked.  Data  was
recorded as percent blocking, meaning the percentage that
entry was reduced compared to controls. Maximum percent
blocking of approximately 45%, 30%, and 20% were seen
when the cells were treated with anti-nectin-1 (Figure 7A),
anti-HVEM  (Figure  7B),  and  anti-PILR-α  (Figure  7C)
antibodies, respectively. Further reduction was seen when
multiple receptors were blocked – there was approximately
50%  blocking  when  the  anti-nectin-1  and  anti-HVEM
antibodies were used in coordination (Figure 7D) and nearly
70% blocking when all three antibodies were used (Figure
7E). Absolute numbers for blocking are shown in Table 1.
Nectin-1 expression may reduce re-infection: The re-infection
experiment was performed to indicate whether HSV-1 entry
was affected by a previous low-level infection. The results
shown in Figure 8 demonstrate a decrease in HSV-1 (gL-86)
Figure 3. HSV-1 entry into HCE cells is a pH dependent process. Monolayers of HCE cells were either mock treated (no treatment) or treated
with indicated concentrations of bafilomycin (A) or chloroquine (B) and exposed to HSV-1(KOS)gL86. Viral entry was measured using a
spectrophotometer at an OD of 410 nm and plotted as the mean of three samples (±SD).
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2481entry  into  cells  that  have  already  undergone  a  primary
infection  with  wild-type  HSV-1  (KOS)  (superinfected)
compared to control, which were not exposed to HSV-1(KOS)
before HSV-1(gL86) expression. To analyze the percentage
of cells that were infected at this time point (48 h after primary
infection), cells were stained for β-galactosidase expression
from the secondary viral genome [27]. The number of cells
infected in by secondary reporter virus averaged at 27±4%
(data not shown) compared to about 100% infected control
cells.  To  gain  insight  into  a  possible  mechanism  for  the
decrease in infection, flow cytometry was performed post-
primary infection to determine nectin-1 expression compared
Figure  4.  Quantitative  RT–PCR  analysis  for  entry  receptor
expression. Total RNA was isolated from HCE and CHO-K1 cells
and converted to cDNA and analyzed by PCR for the receptors as
indicated. A house keeping gene, β-actin (ACTB), was used as a
control (A). Densitometry analysis was performed using the NIH
ImageJ software (Version 1.43) and data for relative intensity was
plotted as a histogram (B).
to control. The results in Figure 9 show a decrease in the level
of  nectin-1  expression  on  living  cells  48  h  post-primary
infection compared to living control cells that underwent no
Figure 5. Immunofluorescence imaging of receptors on HCE cell
membrane.  Images  shown  were  taken  using  the  FITC  filter  of
confocal microscope (Leica SP20). Cells were blocked for 90 min,
washed, and then either mock treated with buffer alone (B, D, F) or
treated with primary antibodies for Nectin-1 (A), HVEM (C), and
PILR-alpha (E). Images were taken after the incubation of HCE cells
with FITC-conjugated secondary antibodies. Staining of cells with
green demonstrate receptor expression.













1:1600 0.79±0.01 0.79±0.02 0.75±0.01 0.78±0.01 0.77±0.01 0.77±0.01
1:800 0.79±0.03 0.72±0.01 0.72±0.01 0.74±0.01 0.72±0.01 0.71±0.01
1:400 0.77±0.02 0.68±0.01 0.7±0.01 0.74±0.01 0.65±0.01 0.54±0.01
1:200 0.78±0.01 0.59±0.02 0.66±0.01 0.7±0.01 0.58±0.01 0.46±0.02
1:100 0.77±0.03 0.55±0.01 0.63±0.01 0.64±0.01 0.48±0.01 0.36±0.02
1:50 0.78±0.02 0.49±0.01 0.54±0.01 0.64±0.01 0.43±0.01 0.32±0.02
1:25 0.78±0.02 0.45±0.02 0.51±0.01 0.62±0.01 0.36±0.02 0.25±0.01
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2482primary infection and instead were simply incubated for 48 h.
This  result,  however,  has  to  be  seen  in  the  light  of  the
observation  that  overall  expression  of  nectin-1  goes  up
significantly from about 24 h of incubation (Figure 6) to after
48 h of incubation. Thus, a prior infection by a HSV-1 strain
can reduce the nectin-1 expression relative to uninfected cells.
DISCUSSION
HSV-1 can infect the cornea and cause keratitis – an often
treatable but potentially visually debilitating disease that can
progress  to  dendritic  ulceration  as  well  as  corneal
neovascularization and scarring through repeated episodes
[1]. HSV-1 epithelial keratitis predisposes to infection of the
deeper layers of the cornea [1,2,8]. The ability of HSV-1 to
develop latent infection in trigeminal ganglia creates the threat
of ocular disease to affected patients throughout their lives
[8,25-27].
While the cornea represents the gateway to infection in
other parts of the eye, little is known of the cellular and
molecular mediators of viral entry into corneal epithelial cells.
As a preliminary step toward understanding this process, our
study  provides  knowledge  on  specific  features  of  HSV-1
entry. We first demonstrated that HSV-1 can successfully
enter and infect the HCE cell line, and that the infection
process relies on the receptors nectin-1, HVEM, and PILR-
α, located on the cell membrane. It was noted that while HCE
cells express all three receptors, cell types show different
expression patterns [28,29].
Importantly, corneal fibroblasts do not express nectin-1
[30]. This may provide some insight into the pathogenesis of
herpetic keratitis; in addition to known features of ocular
herpes pathogenesis, unique virus-cell interactions in the entry
process may occur. HSV-1 entry into trabecular meshwork
cells  is  primarily  facilitated  by  HVEM,  whereas  in
conjunctival epithelial cells it is aided by nectin-1 and HVEM
[25,28,31].
The importance of all three receptors (nectin-1, HVEM,
and PILR-α) for HSV-1 entry was confirmed via antibody-
blocking, which demonstrated decreased viral entry when one
or more receptor was blocked. Maximum reduction of viral
entry was seen when multiple receptors were blocked. The
entry graphs did not plateau and some entry was still observed
when all three antibodies were used with maximal blocking
of 70%. This suggests one of the following: antibody blocking
was incomplete which would otherwise have prevented all
viral entry; 3-O sulfated heparan sulfate plays a role in entry
into HCE cells; there is/are unknown mechanism(s) involved.
Our entry results demonstrated that nectin-1 was the most
significant receptor for entry, followed by HVEM and then
PILR-α. Given current knowledge of the role of PILR-α in
HSV infection, it may more accurately be described as a co-
receptor that aids other primary receptors in entry [21]. Entry
was also shown to be pH dependent and thus may utilize a
vesicular form of entry that relies on acidification [18].
The pathogenesis of corneal epithelial infection by HSV
is not well understood, which includes periods of active virus
during which cellular entry and spread occurs. With episodes
lasting several days, we were interested in re-infection in the
HCE cell line. Our study demonstrated a lower efficiency of
secondary viral infection at 24 to 48 h. Therefore, this is
further evidence that virus-cell interactions may be important
in the infection process. Due to limitations of our in vitro
system we were unable to investigate substantially longer time
points.
To  determine  whether  re-infection  correlated  with  a
change in receptor expression, flow cytometry was performed
to test for levels of nectin-1, which was the primary receptor
in viral entry. The result that average nectin-1 expression was
reduced  after  the  initial  infection  is  an  observation  that
Figure  6.  Flow  cytometry  analysis  of  cell-surface  receptor
expression. Expression was detected by Fluorescence-activated cell
sorter (FACS) analysis. Cells were treated with primary antibodies
to Nectin-1 (A), HVEM (B), or PILR-alpha (C). HCE cells stained
only  with  FITC-conjugated  secondary  antibody  were  used  as
background controls and are shown as the dark gray in the figure.
Molecular Vision 2010; 16:2476-2486 <http://www.molvis.org/molvis/v16/a265> © 2010 Molecular Vision
2483requires  further  investigation.  The  implications  of  this
decrease including whether it plays a role in the trends of re-
infection are future areas of interest.
Studies  are  also  required  to  further  investigate  the
molecular  mechanisms  of  viral  entry  in  the  corneal
epithelium.  As  mentioned,  our  result  that  nectin-1  is  the
primary receptor for entry is in contrast to what is known for
corneal fibroblasts [30]. This is an important consideration for
future therapeutic modalities targeting entry mechanisms. For
instance,  one  may  postulate  that  blocking  nectin-1  may
attenuate  corneal  epithelial  infection,  whereas  for  stromal
infection  this  would  be  less  important.  The  presence  of
nectin-1 in murine corneal epithelium and other ocular tissues
has been described previously [32]. With this in mind, the
roles of nectin-1, HVEM, and PILR-α in corneal epithelial
infection also need to be assessed using in vivo models. The
finding of pH dependency of HSV-1 entry into HCE cells must
Figure 7. Antibodies to the major receptors block HSV-1 entry.
Monolayers of cells plated in 96-well culture dishes were incubated
with serial dilutions of primary antibodies to Nectin-1, HVEM, and
PILR-α for 2 h. Cells were then exposed to HSV-1(KOS)gL86 virus
and  viral  entry  was  measured  6  h  post-infection  using  a
spectrophotometer at an OD of 410 nm. The ratio of entry between
cells treated and those untreated are reported as percent blocking.
Combinations of antibodies that block these receptors were also
studied.  Data  shown  are  the  means  of  triplicate  determinations
(±SD).  Anti-nectin-1  (A),  anti-HVEM  (B),  anti-PILR-α  (C),  a
combination of anti-nectin-1 and anti-HVEM antibodies (D) and a
combination of all three antibodies (E).
also be further probed as this suggests a possible endocytic
mode of entry. The possibility of a pH-altering treatment
could also be studied in vivo, although ocular toxicity would
be an important limiting factor. Finally, reduced secondary
viral entry and changes in expression of entry receptors after
exposure to virus may influence pathogenesis. As HSV-1
infection  of  the  cornea  remains  a  significant  cause  of
Figure  8.  Superinfected  cells  demonstrate  less  viral  entry.
Monolayers of cells plated in 96-well culture dishes were treated with
a primary viral dose of HSV-1(KOS) at an MOI of 0.01. After 48 h
of incubation at 37 °C, cell were treated with serial dilution of a
secondary  viral  dose  of  HSV-1(KOS)gL86.  Viral  entry  was
measured using a spectrophotometer at an OD of 410 nm. Cells solely
infected with only one dose of HSV-1(KOS)gL86 were used as
control.
Figure 9. Cells demonstrate a decreased level of Nectin-1 receptor
expression after primary infection. Monolayers of HCE cells plated
on a 6-well tissue culture dish were treated with a viral dose at an
MOI of 0.01 and incubated for 48 h at 37 °C. Cells were then treated
with  MTT  to  distinguish  live  from  dead  cells.  FACS  was  then
performed to test levels of Nectin-1 on living infected cells tagged
with red fluorescent protein. HCE cells untreated with a viral dose
were used as a control and are shown as the green shade.
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2484morbidity, this study provides important insights to guide
future work.
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